X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Pelosi’s radical plan leaves lung cancer patients behind

By Tom Wilbur  |    October 23, 2019
Lung cancer is the second most common form of cancer in men and women and the leading cause of cancer-related deaths in the United States. In 2019 alone, there will be an estimated 228,000 new...   Read More

Guest post: Sharing discounts and rebates is the right thing to do

By Guest Contributor  |    October 21, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Pelosi’s radical plan would leave Alzheimer’s patients behind

By Tom Wilbur  |    October 16, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and...   Read More

Event tomorrow: Maintaining America’s leadership in access and innovation

By Andrew Powaleny  |    October 16, 2019
Each year, biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high...   Read More

Pelosi’s radical plan would leave ALS patients behind

By Tom Wilbur  |    October 15, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and...   Read More

What They Are Saying: Broad Opposition to Pelosi’s Radical Drug Pricing Plan

By Tom Wilbur  |    October 10, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan that would be the wrong approach for patients, the U.S. health care system, economy, and American innovation. An...   Read More

Nearly 140 medicines in development to treat mental illness

By Andrew Powaleny  |    October 10, 2019
Today is World Mental Health Day, a moment where we reflect about the challenges we still face towards better treatment of mental illness and its impact on patients.   Read More

IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act

By Tom Wilbur  |    October 9, 2019
In our last IP Explained post, we outlined how the Bayh-Dole Act laid the foundation for effective technology transfer across industries in the United States and helps foster continued medical...   Read More

More evidence that medicine prices are growing at slowest rate in decades

By Holly Campbell  |    October 4, 2019
This week the White House Council of Economic Advisers (CEA) released yet another report showing that medicine prices are growing at the slowest rate in decades. The report, “Measuring...   Read More

On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions

By Megan Van Etten  |    October 4, 2019
Each year, the first Friday in October marks Manufacturing Day, an annual recognition of the critical role manufacturing-intensive industries play in powering innovation and generating jobs and...   Read More

The truth about the marketing and promotion of medicines

By Holly Campbell  |    October 3, 2019
Despite what critics say, the U.S. biopharmaceutical industry spends three times more on the research and development (R&D) of new treatments and cures than on the marketing and promotion of...   Read More

Survey shows out-of-pocket costs top health care concern for voters

By Holly Campbell  |    October 2, 2019
A recent national survey of 800 registered voters conducted by Public Opinion Strategies shows that health insurance premiums, deductibles and copays are the top health care concerns for...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates